New hope for rare kidney disease: phase 3 trial of DMX-200 launches
Disease control
Recruiting now
This study tests an experimental drug, DMX-200, in about 286 people with a rare kidney disease called FSGS. The drug aims to reduce protein in the urine and slow down kidney damage. Participants must be 12 to 80 years old and already taking a standard blood pressure medication (A…
Phase: PHASE3 • Sponsor: Dimerix Bioscience Pty Ltd • Aim: Disease control
Last updated May 14, 2026 12:05 UTC